RA
ADVM

Royce & Associates’s Adverum Biotechnologies ADVM Stock Holding History

Royce & Associates’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-9,235
Closed -$380K – 1080
2016
Q3 		$380K Sell
9,235
-10,100
-52% -$383K ﹤0.01% 1015
2016
Q2 		$611K Hold
19,335
– – ﹤0.01% 962
2016
Q1 		$1M Sell
19,335
-6,226
-24% -$348K 0.01% 924
2015
Q4 		$2.43M Buy
25,561
+7,361
+40% +$647K 0.01% 813
2015
Q3 		$1.5M Buy
+18,200
New +$2.33M 0.01% 918

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Royce & Associates's ADVM Position: Q4 2016 in Review

Royce & Associates sold out of Adverum Biotechnologies (ADVM) in Q4 2016, closing a stake of 9,235 shares — an estimated $380K sold.

Royce & Associates first reported a position in ADVM in Q3 2015 and held it in 5 quarters. The position peaked at $2.43M in Q4 2015. 83 funds tracked by Wall St. Rank hold ADVM as of Q4 2016.

  • Royce & Associates reported no remaining Adverum Biotechnologies position as of Q4 2016 after selling out during the quarter.
  • Royce & Associates sold 9,235 Adverum Biotechnologies shares in Q4 2016, an estimated $380K.
  • Royce & Associates first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 5 quarters.
  • Royce & Associates's Adverum Biotechnologies position peaked at $2.43M in Q4 2015.
  • 83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2016.

Based on Royce & Associates's 13F filing for Q4 2016, filed 10 Feb 2017.